UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
November 14, 2005
Date of Report (Date of earliest event reported)
ALLERGAN, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State of Incorporation)
|
|
1-10269
(Commission File Number)
|
|
95-1622442
(IRS Employer
Identification Number) |
2525 Dupont Drive
Irvine, California 92612
(Address of principal executive offices) (Zip Code)
(714) 246-4500
(Registrants telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
þ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On November 15, 2005, Allergan, Inc. (Allergan), issued a press release announcing its
proposal to acquire Inamed Corporation (Inamed). The proposal was communicated on November 14,
2005 in a letter from David E.I. Pyott, Allergans Chairman of the Board, President and Chief
Executive Officer to Nicholas L. Teti, Inameds Chairman of the Board, President and Chief
Executive Officer. The press release announcing the proposal, including the full text of the
proposal letter delivered to Mr. Teti, is attached as Exhibit 99.1 to this Current Report and is
incorporated herein by this reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit |
|
|
No. |
|
Description of Exhibit |
|
|
|
99.1
|
|
Allergan, Inc. press release dated November 15, 2005. |
2